Prognostic significance of DNA flow cytometric analysis in patients with nasopharyngeal carcinoma

Cancer

Volumn 83, Issue 11, 1998, Pages 2284-2292

  Yip, Timothy T C ^a   Lau, W H ^a   Chan, John K C ^a   Ngan, Roger K C ^a   Poon, Y F ^a   Lung, C W ^a   Lo, T Y ^a   Ho, John H C ^b  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^b Baptist Hospital   (Hong Kong)

Author keywords

DNA flow cytometry; DNA ploidy; Nasopharyngeal carcinoma; Prognostic markers; Proliferative fractions; S phase fraction; Survival analysis

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; DIAGNOSTIC VALUE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION;

BIOPSY; CELL DIVISION; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; NASOPHARYNGEAL NEOPLASMS; PLOIDIES; PROGNOSIS; S PHASE; SURVIVAL RATE;

EID: 0032400870     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981201)83:11<2284::AID-CNCR7>3.0.CO;2-J     Document Type: Article

References (63)

1. Ho JHC. Nasopharyngeal carcinoma. Adv Cancer Res 1972; 15:57-92.
2. Huang DP. Epidemiology and aetiology. In: van Hasselt CA, Gibb AG, editors. Nasopharyngeal carcinoma. Hong Kong: Chinese University Press, 1991:23-35.
3. Hong Kong Cancer Registry. Cancer incidence and mortality in Hong Kong 1992. Hong Kong: Hospital Authority Hong Kong, 1996:12.
4. Wei WI, Sham JS, Zong YS, Choy D, Ng MH. The efficacy of fiberoptic endoscopie examination and biopsy in the detection of early nasopharyngeal carcinoma. Cancer 1991;67: 3127-30.
5. Henle G, Henle W. Epstein-Barr virus specific IgA serum antibody as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976;17:1-7.
6. Ho JHC, Ng MH, Kwan HC, Chau JCW. Epstein-Barr virus specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer 1976;34:655-9.
7. Ho JHC, Lau WH, Fong M. Treatment of nasopharyngeal carcinoma (NPC). In: Grundmann E, Krueger GRF, Ablashi DV, editors. Nasopharyngeal carcinoma, cancer campaign. Volume 5. New York: Gustav Fischer Verlag, 1981:279-85.
8. Ho JHC. Nasopharynx. In: Halnan KE, Boak JL, Crowther D, von Essen CE, Orr JS, Peckham MJ, editors. Treatment of cancer. London: Chapman and Hall, 1982:249-67.
9. Mesic JB, Fletcher GH, Geopfert H. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int J Radiat Oncol Biol Phys 1981;7:447-53.
10. Huang SC, Chu GL. Nasopharyngeal cancer: study II. Int J Radiat Oncol Biol Phys 1981;7:713-6.
11. Ho JHC. Stage classification of nasopharyngeal carcinoma: a review. In: De-The G, Ito Y, editors. Nasopharyngeal carcinoma: etiology and control. Lyon: International Agency for Research on Cancer Science Publication, 1978:99-114.
12. Ho JHC. Stage classification of nasopharyngeal carcinoma: a review. In: De-The G, Ito Y, eds. Nasopharyngeal carcinoma: etiology and control. Lyon: International Agency for Research on Cancer Science Publication, 1978:99-114.
13. Teo PM, Leung SF, Yu P, Tsao SY, Foo W, Shiu W. A comparison of Ho's, International Union Against Cancer and American Joint Committee stage classifications for nasopharyngeal carcinoma. Cancer 1991;67:434-9.
14. Lee AWM, Poon YF, Foo W, Law SCK, Cheung FK, Chan DKK, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: over-all survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23:261-70.
15. Yip TTC, Ngan RKC, Lau WH, Poon YF, Joab I, Cochet C, et al. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 1994;74:2414-24.
16. Yip TTC, Lau WH, Ngan RKC, Poon YF, Joab I, Cochet C, et al. Role of Epstein-Barr virus serology in the prognosis of nasopharyngeal carcinoma: the present and the future. Epstein-Barr Virus Rep 1996;3:25-33.
17. Merkel DE, Dressier LG, McGuire WL. Flow cytometry, cellular DNA content and prognosis in human malignancy. J Clin Oncol 1987;5:1690-703.
18. Merkel DE, McGuire WL. Ploidy, proliferative activity and prognosis: DNA flow cytometry of solid tumors. Cancer 1990;65:1194-205.
19. Witzig TE, Ingle JN, Schaid DJ, Wold LE, Barlow JF, Gonochoroff NJ, et al. DNA ploidy and percent S phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials. J Clin Oncol 1993;11:351-9.
20. Ensley JF, Maciorowski Z. Clinical applications of DNA content parameters in patients with squamous cell carcinomas of the head and neck. Semin Oncol 1994;21:330-9.
21. Jones DJ, Moore M, Schofield PF. Refining the prognostic significance of DNA ploidy status in colorectal cancer: a prospective flow cytometric study. Int J Cancer 1988;41:206-10.
22. Isobe H, Miyamoto H, Shimizu T, Haneda H, Hashimoto M, Inoue K, et al. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell carcinoma. Cancer 1990;65:1391-5.
23. Lopez-Beltran A, Croghan GA, Croghan I, Matilla A, Gaeta JF. Prognostic factors in bladder cancer: a pathologic, immunohistochemical and DNA flow-cytometric study. Am J Clin Pathol 1994;102:109-14.
24. Braly PS, Klevecz RR. Flow cytometric evaluation of ovarian cancer. Cancer 1993;71:1621-8.
25. Lutgens LCHW, Schutte B, Jong JMA, Thunnissen FBJM. DNA content as prognostic factor in cervix carcinoma stage IB-III treated with radiotherapy. Gynecol Oncol 1994;54:275-81.
26. Lee AW, Foo W, Poon YF, Lew CK, Chan DK, O SK, et al. Staging of nasopharyngeal carcinoma: evaluation of N-staging by Ho and UICC/AJCC systems. Union Internationale Contre le Cancer, American Joint Committee for Cancer. Clin Oncol (R Coll Radial) 1996;8:146-54.
27. Shanmugaratnam K, Chan SH, de-The G, Goh JEH, Khor TH, Simons MJ, et al. Histopathology of nasopharyngeal carcinoma. Correlations with epidemiology, survival rates and other biologic characteristics. Cancer 1979;44:1029-44.
28. Krueger GRF, Kottaridis SD, Wolf H, Ablashi DV, Sesterhenn K, Bertram G. Histological types of nasopharyngeal carcinomas as compared to EBV serology. Anticancer Res 1981;1: 187-94.
29. Hsu HC, Chen CL, Hsu MM, Lynn TC, Tu SM, Huang SC. Pathology of nasopharyngeal carcinoma. Proposal of a new histologic classification correlated with prognosis. Cancer 1987;59:945-51.
30. McGuire LJ, Lee JCK. The histopathologic diagnosis of nasopharyngeal carcinoma. Ear Nose Throat J 1990;69:229-36.
31. Wu TC, Mann RB, Epstein JI, MacMahon E, Lee WA, Charache P, et al. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma: a morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol 1991;138:1461-9.
32. Yip TTC, Chan JKC, Poon YF, Lau WH, Ngan RKC, Ma VWS. Usefulness of in situ hybridization (ISH) for Epstein-Barr virus encoded RNAs (EBERs) in assisting the histopathological diagnosis of nasopharyngeal carcinoma (NPC) [abstract]. Int J Surg Pathol 1995;2:259.
33. Yip TTC, Chan JKC, Poon YF, Lau WH, Ngan RKC, Ma VWS. Delineation of various factors affecting the sensitivity and specificity of in situ hybridization (ISH) for Epstein-Barr virus encoded RNAs (EBERs) [abstract]. Int J Surg Pathol 1995;2:381.
34. Hedley DW. Flow cytometry using paraffin-embedded tissue: five years on. Cytometry 1989;10:229-41.
35. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, et al. Guideline for implementation of clinical DNA cytometry. Cytometry 1993;14:472-7.
36. Whitney DR. A bivariate extension of the U statistic. Ann Math Stat 1951;22:274-82.
37. Samuels ML. Statistics for the life sciences, 1st edition. San Francisco and London; Collier Macmillan Publishers, 1989.
38. Breslow N. Statistical methods for censored survival data. Environ Health Perspective 1979;32:182-92.
39. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
40. Saunders MI, Dische S, Hong A, Grosch EJ, Fermont DC, Ashford RF, et al. Continuous hyperfractionated accelerated radiotherapy in locally advanced carcinoma of the head and neck region. Int J Radiat Oncol Biol Phys 1989;17:1287-93.
41. Saunders MI, Dische S. Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non small-cell carcinoma of the bronchus. Int J Radiat Oncol Biol Phys 1990;19: 1211-5.
42. Begg AC, Hofland I, Van Glabekke M, Bartlelink H, Horiot JC. Predictive value of potential doubling time for radiotherapy of head and neck tumour patients: results from the EORTC Cooperative Trial 22851. Semin Radiat Oncol 1992;2:22-5.
43. Horiot JC, Bontemps P, Begg AC, Le Fur R, van den Bogaert W, Bolla M, et al. Hyperfractionated and accelerated radiotherapy in head and neck cancers: results of the EORTC trials and impact on clinical practice. Bull Cancer Radiother 1996;83:314-20.
44. Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bella M, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-21.
45. Hall EJ, editor. Radiobiology for the radiologist. 4th edition. Philadelphia: J.B. Lippincott Co., 1994:211-30.
46. Azli N, Armand JP, Rahal M, Wibault P, Boussen H, Eschwege F, et al. Alternating chemo-radiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma of the nasopharyngeal type. Eur J Cancer 1992;28A:1792-7.
47. Tsujii H, Kamada T, Tsuji H, Takamura A, Matsuoka Y, Usubuchi H, et al. Improved results in the treatment of nasopharyngeal carcinoma using combined radiotherapy and chemotherapy. Cancer 1989;63:1668-72.
48. Dimery IW, Peters LJ, Goepfert H, Morrison WH, Byers RM, Guillory C, et al. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol 1993;11:1919-28.
49. Al-Sarraf M, Pajak TF, Cooper JS, Mohiuddin M, Herskovic A, Ager PJ. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a Radiation Therapy Oncology Group Study. J Clin Oncol 1990;8:1342-51.
50. Chan ATC, Teo PML, Leung WT, Leung TWT, Leung SF, Lee WY, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995;33:569-77.
51. Rossi A, Molinari R, Boracchi P, Del Vechio M, Marubini E, Nava M, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicentre randomized study. J Clin Oncol 1988;6:1401-10.
52. Cvitkovic E. Neoadjuvant chemotherapy with epirubicin, cisplatin, bleomycin (BEC) in undifferentiated nasopharyngeal cancer: preliminary results of an international phase III trial. Proc Am Soc Clin Oncol 1994;13:283.
53. Cheng SH, Liu TW, Jian JJ, Tsai SY, Hao SP, Huang CH, et al. Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma. Cancer J Sci Am 1997; 3:100-6.
54. Lin JC, Jan JS, Hsu CY. Pilot study of concurrent chemotherapy and radiotherapy for stage IV nasopharyngeal cancer. Am J Clin Oncol 1997;20:6-10.
55. Steel GG. Tumor growth kinetics. In: Steel GG, Adams GE, Horwich A, editors. The biological basis of radiotherapy. 3rd edition. Amsterdam: Elsevier Science Publishers, 1995;8-13.
56. Tannock IF. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumor. Br J Cancer 1968;22:258-73.
57. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic micro-environment of human tumors: a review. Cancer Res 1989;49:6449-65.
58. Costello F, Mason BR, Collins RJ, Kearsley JH. A clinical and flow cytometric analysis of patients with nasopharyngeal cancer. Cancer 1990;66:1789-95.
59. Reddy SP, Raslan WF, Gooneratne S, Kathuria S, Marks JE. Prognostic significance of keratinization in nasopharyngeal carcinoma. Am J Otolaryngol 1995;16:103-8.
60. Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol 1994;21:376-81.
61. Kokal WA, Gardine RL, Sheibani K, Zak IW, Beatry JD, Riihimaki DU, et al. Tumor DNA content as a prognostic indicator in squamous cell carcinoma of the head and neck region. Am J Surg 1988;156:276-80.
62. Hemmer J, Kriedler J. Flow cytometric DNA ploidy analysis of squamous cell carcinoma of the oral cavity. Comparison with clinical staging and histologic grading. Cancer 1990;66: 317-20.
63. Rua S, Comino A, Fruttero A, Cera G, Semeria C, Lanzillotta L, et al. Relationship between histologic features, DNA flow cytometry, and clinical behavior of squamous cell carcinomas of the larynx. Cancer 1991;67:141-9.